Novo Up, Orsted Gains, M&S Dips
On this episode of Stock Movers:- Novo Nordisk pared its forecast for a fourth time this year on lagging sales of its blockbuster drugs Wegovy and Ozempic, underscoring the urgency facing its new CEO.- Orsted has confirmed its full-year profit guidance, seeking to reassure investors of its financial stability after a weak third quarter..- M&S expects profit in the second half to rebound to at least last year’s level as the British retailer tries to move on from a costly cyberattack.See omnystudio.com/listener for privacy information.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.